Last reviewed · How we verify

NCT04781010

Characterization and Outcome of Children With Leukodystrophy: An Observational Study at Sohag University Hospital

Status unknown Last updated 4 March 2021
What this trial tests

trial testing MRI in Children With Leukodystrophy in 100 participants. Status unknown.

Timeline
1 March 2021
Primary endpoint
31 March 2023
31 March 2023

Quick facts

Lead sponsorSohag University
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment100
Start date1 March 2021
Primary completion31 March 2023
Estimated completion31 March 2023

Drugs / interventions tested

Conditions studied

Sponsor

Sohag University

Who can join

Adults 0 to 18, any sex, with Children With Leukodystrophy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Leukodystrophies are heterogeneous genetic disorders characterized by the selective involvement of white matter in the central nervous system (CNS) (1, 2). Inherited leukodystrophies are diseases of the myelin, including abnormal myelin development, hypomyelination, or degeneration of myelin (3, 4). Most of these disorders fall into one of three categories; lysosomal storage diseases, peroxisomal disorders, and diseases caused by mitochondrial dysfunction and each leukodystrophy has distinctive clinical, biochemical, pathologic, and radiologic features (5).

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of MRI

Trials testing the same drug.

Other Sohag University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04781010.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing